318 related articles for article (PubMed ID: 36385236)
21. Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma.
Gao Y; Li S; Xu D; Chen S; Cai Y; Jiang W; Zhang X; Sun J; Wang K; Chang B; Wang F; Hong M
Chin J Cancer; 2017 Jul; 36(1):61. PubMed ID: 28754154
[TBL] [Abstract][Full Text] [Related]
22. Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer.
Sanchez K; Kim I; Chun B; Pucilowska J; Redmond WL; Urba WJ; Martel M; Wu Y; Campbell M; Sun Z; Grunkemeier G; Chang SC; Bernard B; Page DB
Breast Cancer Res; 2021 Jan; 23(1):2. PubMed ID: 33413574
[TBL] [Abstract][Full Text] [Related]
23. Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis.
Duchnowska R; Pęksa R; Radecka B; Mandat T; Trojanowski T; Jarosz B; Czartoryska-Arłukowicz B; Olszewski WP; Och W; Kalinka-Warzocha E; Kozłowski W; Kowalczyk A; Loi S; Biernat W; Jassem J;
Breast Cancer Res; 2016 Apr; 18(1):43. PubMed ID: 27117582
[TBL] [Abstract][Full Text] [Related]
24. The Prognostic Value of CD39 as a Marker of Tumor-Specific T Cells in Triple-Negative Breast Cancer in Asian Women.
Meng J; Tan JYT; Joseph CR; Ye J; Lim JCT; Goh D; Xue Y; Lim X; Koh VCY; Wee F; Tay TKY; Chan JY; Ng CCY; Iqbal J; Lau MC; Lim HE; Toh HC; Teh BT; Dent RA; Tan PH; Yeong JPS
Lab Invest; 2024 Mar; 104(3):100303. PubMed ID: 38103870
[TBL] [Abstract][Full Text] [Related]
25. Histological spatial analysis on the induction of PD-L1
Suzuki K; Ohe R; Kabasawa T; Kitaoka T; Kawai M; Motoi F; Futakuchi M
Breast Cancer; 2023 Nov; 30(6):1094-1104. PubMed ID: 37792212
[TBL] [Abstract][Full Text] [Related]
26. Effects of tumor-infiltrating CD8+ T cells, PD1/PD-L1 axis, and expression patterns of HLA class I on the prognosis of patients with malignant pleural mesothelioma who underwent extra-pleural pneumonectomy.
Okita R; Mimura-Kimura Y; Kawamoto N; Yamamoto N; Umeda M; Okada M; Inokawa H; Mimura Y; Murakami T; Nakata M; Okabe K
Cancer Immunol Immunother; 2023 Apr; 72(4):865-879. PubMed ID: 36115921
[TBL] [Abstract][Full Text] [Related]
27. PD-L1 (SP142) Expression in Primary and Recurrent/Metastatic Triple-Negative Breast Cancers and Its Clinicopathological Significance.
Han EK; Woo JW; Suh KJ; Kim SH; Kim JH; Park SY
Cancer Res Treat; 2024 Apr; 56(2):557-566. PubMed ID: 38097920
[TBL] [Abstract][Full Text] [Related]
28. TNFR2+ TILs are significantly associated with improved survival in triple-negative breast cancer patients.
Dadiani M; Necula D; Kahana-Edwin S; Oren N; Baram T; Marin I; Morzaev-Sulzbach D; Pavlovski A; Balint-Lahat N; Anafi L; Wiemann S; Korner C; Gal-Yam EN; Avivi C; Kaufman B; Barshack I; Ben-Baruch A
Cancer Immunol Immunother; 2020 Jul; 69(7):1315-1326. PubMed ID: 32198536
[TBL] [Abstract][Full Text] [Related]
29. Correlation between stromal Th and Tc lymphocytes and PD-L1 expression in early breast cancer tumors.
Vučinić J; Vučković L; Raonić J
Folia Histochem Cytobiol; 2023; 61(4):193-204. PubMed ID: 38073318
[TBL] [Abstract][Full Text] [Related]
30. [Evaluation of the predictive effect of PD-L1 expression on survival in early triple-negative breast cancer].
Yue J; Wang X; Zhu AJ; Wang DY; Gao SL; Hu NL; Si YR; Zheng FC; Ju J; Wang Z; Yuan P
Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):948-954. PubMed ID: 37968080
[No Abstract] [Full Text] [Related]
31. Granzyme B Expression in the Tumor Microenvironment as a Prognostic Biomarker for Patients with Triple-Negative Breast Cancer.
Mizoguchi K; Kawaji H; Kai M; Morisaki T; Hayashi S; Takao Y; Yamada M; Shimazaki A; Osako T; Arima N; Okido M; Oda Y; Nakamura M; Kubo M
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760424
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathological factors associated with tumor-infiltrating lymphocyte reactivity in breast cancer.
Lee H; Kim YA; Kim Y; Park HS; Seo JH; Lee H; Gong G; Lee HJ
Cancer Immunol Immunother; 2020 Nov; 69(11):2381-2391. PubMed ID: 32529292
[TBL] [Abstract][Full Text] [Related]
33. The prognostic value of a combined immune score in tumor and immune cells assessed by immunohistochemistry in triple-negative breast cancer.
Choi JE; Lee JS; Jin MS; Nikas IP; Kim K; Yang S; Park SY; Koh J; Yang S; Im SA; Ryu HS
Breast Cancer Res; 2023 Nov; 25(1):134. PubMed ID: 37924153
[TBL] [Abstract][Full Text] [Related]
34. Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer.
Lopez de Rodas M; Nagineni V; Ravi A; Datar IJ; Mino-Kenudson M; Corredor G; Barrera C; Behlman L; Rimm DL; Herbst RS; Madabhushi A; Riess JW; Velcheti V; Hellmann MD; Gainor J; Schalper KA
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35649657
[TBL] [Abstract][Full Text] [Related]
35. PROGRAMMED CELL DEATH LIGAND 1 (PD-L1) EXPRESSION IN TRIPLE NEGATIVE BREAST CANCER CASES IN BENIN CITY.
Owolabi DO; Olu-Eddo AN; Ekanem VJ; Udoh MO; Ogunbiyi JO; Obaseki DE; Obahiagbon I; Asogwa K; Nwagoh B; Aniume O; Ugiagbe EE; Forae GD; Imasogie DE
West Afr J Med; 2023 Dec; 40(12 Suppl 1):S35. PubMed ID: 38070139
[TBL] [Abstract][Full Text] [Related]
36. Correlation between PD-L1 expression of the tumour cells and lymphocytes infiltration in the invasive front of urothelial carcinoma.
Chen X; Chen H; Lin R; Li Y; Guo Y; Chen Q; Zhang Y; Cai G; Hu M; Chen G
J Clin Pathol; 2023 Dec; 77(1):61-67. PubMed ID: 36319076
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of PD-1/PD-L1 expression in uveal melanoma: correlation with tumor-infiltrating lymphocytes and clinicopathological parameters.
Singh L; Singh MK; Kenney MC; Jager MJ; Rizvi MA; Meel R; Lomi N; Bakhshi S; Sen S; Kashyap S
Cancer Immunol Immunother; 2021 May; 70(5):1291-1303. PubMed ID: 33136179
[TBL] [Abstract][Full Text] [Related]
38. C-X-C Motif Chemokine Ligand 9 Correlates with Favorable Prognosis in Triple-Negative Breast Cancer by Promoting Immune Cell Infiltration.
Cao X; Song Y; Wu H; Ren X; Sun Q; Liang Z
Mol Cancer Ther; 2023 Dec; 22(12):1493-1502. PubMed ID: 37669562
[TBL] [Abstract][Full Text] [Related]
39. Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial.
Di Bartolomeo M; Morano F; Raimondi A; Miceli R; Corallo S; Tamborini E; Perrone F; Antista M; Niger M; Pellegrinelli A; Randon G; Pagani F; Martinetti A; Fucà G; Pietrantonio F;
Oncologist; 2020 Mar; 25(3):e460-e468. PubMed ID: 32162808
[TBL] [Abstract][Full Text] [Related]
40. Tumor infiltrating lymphocytes (TILs) are a prognosis biomarker in Colombian patients with triple negative breast cancer.
Huertas-Caro CA; Ramírez MA; Rey-Vargas L; Bejarano-Rivera LM; Ballen DF; Nuñez M; Mejía JC; Sua-Villegas LF; Cock-Rada A; Zabaleta J; Fejerman L; Sanabria-Salas MC; Serrano-Gomez SJ
Sci Rep; 2023 Dec; 13(1):21324. PubMed ID: 38044375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
